Saad Usmani to Frailty
This is a "connection" page, showing publications Saad Usmani has written about Frailty.
Connection Strength
0.554
-
Mian H, Faisal MS, Chen T, Brazauskas R, Oloyede T, Ahmed N, Afrough A, Anderson LD, Banerjee R, Berdeja J, Bidikian A, Devos J, Dhakal B, Dias A, Dima D, Efebera YA, Gowda L, Hansen DK, Hashmi H, Landau HJ, Lekakis L, Mirza AS, Narra R, Patel K, Rosko AE, Schroeder M, Sidana S, Usmani S, Pasquini MC, Nishihori T, Akhtar OS, Mohan M. Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. Cancer. 2026 Oct 01; 132(19):e70614.
Score: 0.210
-
Adegbite B, Tan CR, Shekarkhand T, Firestone RS, Jurgens EM, Miller K, Lesokhin AM, Shah GL, Korde N, Rajeeve S, Landau HJ, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz M, Hamadeh IS, Derkach A, Nemirovsky D, Giralt SA, Mailankody S, Usmani SZ, Hashmi H. Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma. Blood Adv. 2025 Aug 12; 9(15):4016-4022.
Score: 0.194
-
Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, Touzeau C, Bahlis NJ, Basu S, Nahi H, Goldschmidt H, Quach H, Mohty M, Venner CP, Weisel K, Raje N, Hebraud B, Belhadj-Merzoug K, Benboubker L, Decaux O, Manier S, Caillot D, Ukropec J, Pei H, Van Rampelbergh R, Uhlar CM, Kobos R, Zweegman S. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022 04; 36(4):1066-1077.
Score: 0.151